A Multicenter Registry Study of Breast Microseed Treatment for Early Stage Breast Cancer

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Radiation
Study Type: Observational
SUMMARY

For women diagnosed with early stage breast cancer, lumpectomy followed by radiation is a common treatment option. Radiation treatment is typically delivered to the whole breast, five times per week, for anywhere from 3 to 8 weeks. The radiation helps kill any cancer cells that may have been left over following the surgery but causes skin burns. Many studies have demonstrated that radiation to the whole breast is not necessary, that it can be delivered to a portion of the breast where the cancer is more likely to recur. A technique called a Permanent Breast Seed Implant (PBSI) involving the implantation of radioactive seeds has been developed to deliver the radiation to a portion of the breast. The procedure is performed on an out-patient basis under local anesthesia and light sedation. Because the radioactive seeds are permanently implanted in the breast, the patient is able to live a normal life while the seeds deliver the prescribed radiation to the breast. Previous studies on PBSI demonstrate that it is a safe and effective alternative form of radiation for appropriately selected patients after lumpectomy. However, those results have been obtained mainly from a single institution, with only 4 patients treated in another center. Further research is still needed to evaluate its safety in a multi-center setting. The purpose of this study is to ensure the appropriate training of clinicians who will be performing this procedure and to capture long term outcomes and rare complications if any.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 50
Healthy Volunteers: f
View:

• Histological diagnosis of invasive or in-situ ductal carcinoma (DCIS)

• Treated by breast conserving surgery with axillary node dissection (with a minimum of 6 nodes sampled) or sentinel lymph node biopsy

• Surgical margins clear for invasive carcinoma (no tumor at ink margin) or superior or equal to 2 mm for in-situ ductal carcinoma (DCIS)

• A maximum tumor size of 3 cm

• Age ≥50 years old

• Informed consent signed if participating in the Registry

Locations
United States
Pennsylvania
Allegheny General Hospital
RECRUITING
Pittsburgh
Virginia
Mary Washington Hospital
RECRUITING
Fredericksburg
Washington
Swedish Cancer Institute
RECRUITING
Seattle
Contact Information
Primary
Juanita Crook, MD
jcrook@bccancer.bc.ca
+1 250 712 3958
Backup
Jean-Philippe Pignol, MD, PhD
j.p.pignol@erasmusmc.nl
+31 10 704 13 66
Time Frame
Start Date: 2016-07
Estimated Completion Date: 2026-07
Participants
Target number of participants: 420
Treatments
Permanent Breast Seed Implant (PBSI)
Women with eligible early stage breast cancer who received a permanent breast seed implant status post lumpectomy
Related Therapeutic Areas
Sponsors
Leads: Concure Oncology-Breast Microseed Inc.

This content was sourced from clinicaltrials.gov